Sublingual semaglutide offered to UK practices despite Novo Nordisk concerns
An unlicensed semaglutide-based product that is administered under the tongue is being marketed to private doctors in the UK despite…
News
J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout
miRecule and Rio Biofarma to develop RNA therapeutic delivery technologies
Resilience and Lilly to increase US medicines production with $750m investment
Pfizer seeks label expansion for Litfulo after double Phase III NSV win
EU regulatory roundup: AbbVie, Pfizer & BioNTech and Incyte net approvals
FDA AdCom shuns Capricor’s DMD cell therapy amid data dispute
The $1.2tn untapped pharma opportunity in tropical conservation
